©DANIEL ROUSSELOT/Sanofi

Sanofi’s Commitment to Hematology

Originally published on Sanofi.com.

Blood cancers and rare blood disorders account for some of the most challenging diseases to treat, and patients often have limited therapeutic options available to them. Sanofi is committed to significantly improving the health and lives of people with a range of hematologic conditions.

Across these therapeutic areas, Sanofi is focused on a number of diseases where patients need new treatment options, including hemophilia, cold agglutinin disease, acquired thrombotic thrombocytopenic purpura and multiple myeloma.

Sanofi’s Commitment to Hematology
Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, and John Reed, Global Head of Research and Development, share their insights on how Sanofi is drawing on its deep expertise in hematology and robust R&D programs to address numerous hematologic conditions.

Latest News

Wells Fargo: This Juneteenth, a Moment of Reflection

As racial injustice issues roil the U.S. and the world, Wells Fargo employees reflect on history and take part in critical and courageous conversations Originally published on stories.wf.com. Juneteenth, a combination of the words “June” and “nineteenth,” commemorates the day when news of the end of enslaved people in the United…

COVID-19’s Impact on the Labor Market Forced a New “Normal” on the U.S. Workforce, Affecting Nearly Every Worker in the U.S.

Originally posted on ADP.com ADP Research Institute® uncovers that despite COVID-19’s significant impact on the workforce, worker confidence and outlook has stabilized A recent survey of workers in the U.S. from the ADP Research Institute reveals that an initially significant decrease in worker confidence appears to be leveling off despite the impact the COVID-19…

orientation, court, gender

In Landmark Case, Supreme Court Declares Federal Law Protects LGBTQ+ Individuals From Job Discrimination

On Monday morning, the Supreme Court ruled that existing federal law forbids job discrimination based on sexual orientation or gender identity. The ruling is a landmark victory for the LGBTQ+ community, and a surprising decision coming from a majority conservative court. In a 6–3 vote, the Court ruled that Title…